Merck Serono and Pfizer are to work with the Broad Institute in Cambridge, Massachusetts to undertake genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients.

Further confirmatory data will be necessary to maintain its approval in the US, where it will be co-marketed by EMD Serono, German Merck’s US biopharma business, and Pfizer. The drug was ...

EMD Serono, the American drug development arm of Germany’s Merck KGaA, plans to move its headquarters from the South Shore town of Rockland to Boston’s Seaport district next summer.

In 2003 Merck Serono, a world leader in the field of biotechnology engaged PDD to design an auto-injector for its Growth Hormone (GH) therapy product Saizen®. In what was a saturated and static market ...

The Foundation of the Consortium of Multiple Sclerosis Centers was gifted $100,000 by EMD Serono for its nursing scholarship ...

In March, Merck Serono, a division of Merck KGaA of Darmstadt, Germany, launched a €40 ($51) million venture capital fund aimed at providing startup companies with opportunities to develop new ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

This week’s quarterly results from Merck looked pretty good, all things considered: Sales and earnings came in ahead of Wall ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Merck, a leading science and technology company, has opened its new €290 million biosafety testing facility in Rockville, ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...